The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial

Sene, Azadeh Akbari; Tabatabaie, Azam; Nikniaz, Hossein; Alizadeh, Ahad; Sheibani, Kourosh; Alisaraie, Mona Mortezapour; Tabatabaie, Maryam; Ashrafi, Mahnaz; Amjadi, Fatemehsadat

doi:10.1007/s00404-019-05111-1

Cited by 22 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The participants, aged 20-35 years and with partner's normal semen analysis, were randomly divided in two groups: the study group received a daily dose of 4 g myo-ins, combined with 400 mcg folic acid (FA); the control group received only 400 mcg FA. Treatment started one month before ovum pick up in both groups [43]. The results demonstrated that the percentage of metaphase II (MII) oocytes, named mature oocytes, and fertilization rate significantly increased in the study group compared with controls.…”

Section: Improvement Of the Ovulation Quality-oogenesismentioning

confidence: 93%

“…In addition, the authors reported that the embryo quality improved after treatment with myoins. Furthermore, the study group exhibited a higher gene expression of phosphoglycerate kinase 1 (PGK1), regulator of G-protein signaling 2 (RGS2) and cell division control protein 42 homolog (CDC42), considered marker genes of oocyte quality in granulosa cells [43].…”

Section: Improvement Of the Ovulation Quality-oogenesismentioning

confidence: 99%

See 1 more Smart Citation

Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth

Russo¹,

Forte²,

Oliva

et al. 2021

IJMS

View full text Add to dashboard Cite

Human pregnancy is a sequence of events finely tuned by several molecular interactions that come with a new birth. The precise interlocking of these events affecting the reproductive system guarantees safe embryo formation and fetal development. In this scenario, melatonin and myo-inositol seem to be pivotal not only in the physiology of the reproduction process, but also in the promotion of positive gestational outcomes. Evidence demonstrates that melatonin, beyond the role of circadian rhythm management, is a key controller of human reproductive functions. Similarly, as the most representative member of the inositol’s family, myo-inositol is essential in ensuring correct advancing of reproductive cellular events. The molecular crosstalk mediated by these two species is directly regulated by their availability in the human body. To date, biological implications of unbalanced amounts of melatonin and myo-inositol in each pregnancy step are growing the idea that these molecules actively contribute to reduce negative outcomes and improve the fertilization rate. Clinical data suggest that melatonin and myo-inositol may constitute an optimal dietary supplementation to sustain safe human gestation and a new potential way to prevent pregnancy-associated pathologies.

show abstract

Section: Improvement Of the Ovulation Quality-oogenesismentioning

confidence: 93%

Section: Improvement Of the Ovulation Quality-oogenesismentioning

confidence: 99%

Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth

Russo¹,

Forte²,

Oliva

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The oocytes from the couples of the spouses divided into two groups and subjected to ICSI with the spermatozoa from the control and treatment groups. They were then cultured in SAGE 1‐StepTM (ORIGIO, Denmark) at 37°C temperature, 90% humidity and 6% CO2 for 3 days (Sene et al, 2019). Fertilization was checked 16 to 18 h after ICSI by the presence of two pronuclei (2PN) and the second polar body.…”

Section: Methodsmentioning

confidence: 99%

GM–CSF (granulocyte‐macrophage colony‐stimulating factor) treatment improves sperm parameters in men with oligoasthenoteratospermia via PI3K/AKT pathway

et al. 2022

Self Cite

View full text Add to dashboard Cite

Poor sperm quality in oligoasthenoteratospermia patients negatively affects assisted reproductive technology outcomes. Therefore, the development of sperm media is necessary to improve sperm parameters. This study investigated the effect of GM‐CSF via PI3K/AKT pathway on sperm quality in OAT patients. Semen samples were collected from 20 OAT patients, and each sample was divided into two groups: Experiment and Control. In the experimental group, the samples were incubated with medium containing GM‐CSF, and control samples were incubated without GM‐CSF. Sperm parameters, mitochondrial membrane potential, acrosome reaction and DFI were studied; in addition, gene expression of PI3KR1, PI3KCA, GLUT1, GLUT3 and AKT1 was analysed, evaluation of PAKT/TAKT, and expression of GLUT 1, 3 was examined; subsequent fertilization rate and embryo quality were assessed. Our data showed that GM‐CSF supplementation could significantly increase motility, mitochondrial activity, gene expression of PI3KCA, AKT1, the protein level of PAKT/TAKT and expression of GLUT 1, 3 while it decreases DNA fragmentation. The fertilization rate and embryo quality significantly improved in the treatment group. LY294002 had adverse effects on sperm motility and the PAKT/TAKT ratio. GM‐CSF can improve in vitro sperm quality and could be a suitable supplement to sperm media for OAT patients.

show abstract

“…Following title and abstract screening, 408 full-text articles were retrieved and screened for eligibility. Of them, 307 articles were excluded, and 101 RCTs [20-32, 33, 34-43, 44, 45- [121][122][123][124][125][126][127][128][129][130][131][132][133][134][135][136], however, they could not be added to our analysis due to the following causes: five studies failed to meet our BMI criteria , three studies included irrelevant interventions [133][134][135], two studies had an open-label design [127,128], two studies measured different outcomes [131,132], one study had a cost-effectiveness design [121], one study had a post-hoc design [129], one study had no treatment control [122], and one study included pregnant patients [130]. Additionally, the bibliography of the included RCTs was manually searched, but no further records were added.…”

Section: Characteristics and Quality Of Included Studiesmentioning

confidence: 99%

The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials

et al. 2021

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) affects up to 18% of reproductive-age females. The prevalence of obesity in PCOS patients reaches up to 80%, which is 2-fold higher than the general population. Objective The present study aimed to compare the effectiveness of 55 pharmacological interventions across 17 different outcomes in overweight/obese PCOS patients with hyperandrogenism manifestations for both short- and long-term follow-ups. A comprehensive literature search was performed on PubMed, Scopus, Embase, Science Direct, Web of Science, and Cochrane CENTRAL for randomized controlled trials comparing any conventional pharmacological intervention as a monotherapy or a combination in overweight/obese patients with polycystic ovary syndrome and hyperandrogenism manifestations. Extracted data included three main parameters; I. Anthropometric parameters (BMI, Waist and Hip circumferences, and Waist/HIP ratio), II. Hormonal parameters (FSH, LH, FSG, SHBG, Estradiol, Total Testosterone, Free testosterone, DHEAS, Androstenedione), and III. Metabolic parameters (Total Cholesterol, LDL-C, HDL-C, Triglycerides, Fasting glucose, Fasting glucose, HOMA-IR). Critical appraisal and risk of bias assessments were performed using the modified Jadad scale, and the overall quality of this network meta-analysis was evaluated according to the CINeMA framework. We performed both a pairwise meta-analysis and a network meta-analysis to evaluate the effect sizes with 95% CI, and we calculated the surface under the cumulative ranking curve (SUCRA) for each intervention. Results Our final search on May 15th 2021 retrieved 23,305 unique citations from searching six electronic databases. Eventually, 101 RCTs of 108 reports with a total of 8,765 patients were included in our systematic review and multi-treatments meta-analysis. 55 different interventions were included: 22 monotherapies, and 33 combinations. The two-dimensional cluster ranking of the average SUCRA values for metabolic and hormonal parameters with significant estimates revealed flutamide (77.5%, 70%; respectively) as the highest and rosiglitazone (38.2%, 26.3%; respectively) as the lowest, in terms of the overall efficacy in reducing weight and hyperandrogenism. However, cyproterone-acetate+ethinylestradiol exhibited a higher ranking in improving hormonal parameters (71.1%), but even a lower-ranking regarding metabolic parameters (34.5%). Conclusions and relevance Current evidence demonstrated the superiority of flutamide in improving both metabolic and hormonal parameters, and the higher efficacy of cyproterone-acetate+ethinylestradiol only in improving hormonal parameters. Nearly all interventions were comparable in female hormones, FGS, HDL, glucose, and insulin levels improvements.

show abstract

The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial

Cited by 22 publications

References 34 publications

Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth

Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth

GM–CSF (granulocyte‐macrophage colony‐stimulating factor) treatment improves sperm parameters in men with oligoasthenoteratospermia via PI3K/AKT pathway

The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials

Contact Info

Product

Resources

About